Role of the growth hormone-IGF-1 axis in cancer

Yash Chhabra; Michael J Waters; Andrew J Brooks

doi:10.1586/eem.10.73

Role of the growth hormone-IGF-1 axis in cancer

Yash Chhabra, Michael J Waters, Andrew J Brooks

Cancer Signaling and Microenvironment (CSM)

University of Queensland

Research output: Contribution to journal › Article › peer-review

76 Scopus citations

Abstract

A substantial body of evidence supports a role for the growth hormone (GH)-IGF-1 axis in cancer incidence and progression. This includes epidemiological evidence relating elevated plasma IGF-1 to cancer incidence as well as a lack of cancers in GH/IGF-1 deficiency. Rodent models lacking GH or its receptor are strikingly resistant to the induction of a wide range of cancers, and treatment with the GH antagonist pegvisomant slows tumor progression. While GH receptor expression is elevated in many cancers, autocrine GH is present in several types, and overexpression of autocrine GH can induce cell transformation. While the mechanism of autocrine action is not clear, it does involve both STAT5 and STAT3 activation, and probably nuclear translocation of the GH receptor. Development of a more potent GH receptor antagonist or secretion inhibitor is warranted for cancer therapy.

Original language	English
Pages (from-to)	71-84
Number of pages	14
Journal	Expert Review of Endocrinology and Metabolism
Volume	6
Issue number	1
DOIs	https://doi.org/10.1586/eem.10.73
State	Published - Dec 2011

Keywords

GH receptor
autocrine GH
breast cancer
colon cancer
epidemiology
growth hormone
insulin-like growth factor-1
nuclear GH receptor
prolactin
prostate cancer
signal transducer and activator of transcription-5

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/eem.10.73

Cite this

@article{21651bfa0ad84a49bc660660523bffe0,

title = "Role of the growth hormone-IGF-1 axis in cancer",

abstract = "A substantial body of evidence supports a role for the growth hormone (GH)-IGF-1 axis in cancer incidence and progression. This includes epidemiological evidence relating elevated plasma IGF-1 to cancer incidence as well as a lack of cancers in GH/IGF-1 deficiency. Rodent models lacking GH or its receptor are strikingly resistant to the induction of a wide range of cancers, and treatment with the GH antagonist pegvisomant slows tumor progression. While GH receptor expression is elevated in many cancers, autocrine GH is present in several types, and overexpression of autocrine GH can induce cell transformation. While the mechanism of autocrine action is not clear, it does involve both STAT5 and STAT3 activation, and probably nuclear translocation of the GH receptor. Development of a more potent GH receptor antagonist or secretion inhibitor is warranted for cancer therapy.",

keywords = "GH receptor, autocrine GH, breast cancer, colon cancer, epidemiology, growth hormone, insulin-like growth factor-1, nuclear GH receptor, prolactin, prostate cancer, signal transducer and activator of transcription-5",

author = "Yash Chhabra and Waters, {Michael J} and Brooks, {Andrew J}",

year = "2011",

month = dec,

doi = "10.1586/eem.10.73",

language = "English",

volume = "6",

pages = "71--84",

journal = "Expert Review of Endocrinology and Metabolism",

issn = "1744-6651",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - Role of the growth hormone-IGF-1 axis in cancer

AU - Chhabra, Yash

AU - Waters, Michael J

AU - Brooks, Andrew J

PY - 2011/12

Y1 - 2011/12

N2 - A substantial body of evidence supports a role for the growth hormone (GH)-IGF-1 axis in cancer incidence and progression. This includes epidemiological evidence relating elevated plasma IGF-1 to cancer incidence as well as a lack of cancers in GH/IGF-1 deficiency. Rodent models lacking GH or its receptor are strikingly resistant to the induction of a wide range of cancers, and treatment with the GH antagonist pegvisomant slows tumor progression. While GH receptor expression is elevated in many cancers, autocrine GH is present in several types, and overexpression of autocrine GH can induce cell transformation. While the mechanism of autocrine action is not clear, it does involve both STAT5 and STAT3 activation, and probably nuclear translocation of the GH receptor. Development of a more potent GH receptor antagonist or secretion inhibitor is warranted for cancer therapy.

AB - A substantial body of evidence supports a role for the growth hormone (GH)-IGF-1 axis in cancer incidence and progression. This includes epidemiological evidence relating elevated plasma IGF-1 to cancer incidence as well as a lack of cancers in GH/IGF-1 deficiency. Rodent models lacking GH or its receptor are strikingly resistant to the induction of a wide range of cancers, and treatment with the GH antagonist pegvisomant slows tumor progression. While GH receptor expression is elevated in many cancers, autocrine GH is present in several types, and overexpression of autocrine GH can induce cell transformation. While the mechanism of autocrine action is not clear, it does involve both STAT5 and STAT3 activation, and probably nuclear translocation of the GH receptor. Development of a more potent GH receptor antagonist or secretion inhibitor is warranted for cancer therapy.

KW - GH receptor

KW - autocrine GH

KW - breast cancer

KW - colon cancer

KW - epidemiology

KW - growth hormone

KW - insulin-like growth factor-1

KW - nuclear GH receptor

KW - prolactin

KW - prostate cancer

KW - signal transducer and activator of transcription-5

UR - http://www.scopus.com/inward/record.url?scp=78650532040&partnerID=8YFLogxK

U2 - 10.1586/eem.10.73

DO - 10.1586/eem.10.73

M3 - Article

C2 - 30764037

SN - 1744-6651

VL - 6

SP - 71

EP - 84

JO - Expert Review of Endocrinology and Metabolism

JF - Expert Review of Endocrinology and Metabolism

IS - 1

ER -

Role of the growth hormone-IGF-1 axis in cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this